Lanreotid Amdipharm (Lanreotide Acetate)

Lanreotide acetate mimics the natural hormone somatostatin and binds preferentially to somatostatin receptor subtypes 2 and 5 on pituitary and neuroendocrine cells. This interaction inhibits adenylate cyclase, lowers cyclic AMP, and blocks calcium‑mediated secretion, resulting in reduced release of growth hormone, IGF‑1, and other tumor‑derived peptides.

The dosing regimen for Lanreotid Amdipharm is individualized by the prescribing physician based on the patient’s clinical condition, disease severity, and response to therapy. The prescriber determines the appropriate injection volume, frequency, and any necessary adjustments during treatment.

Safety data for lanreotide acetate in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs possible risks to the fetus or infant, and treatment decisions should involve a qualified obstetric or neonatal specialist.

To request Lanreotid Amdipharm, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lanreotid Amdipharm (lanreotide) and other agents such as octreotide share a similar mechanism of binding somatostatin receptors, but they differ in dosing frequency, formulation, and pharmacokinetic profile. Lanreotide is often administered as a long‑acting depot injection, allowing less frequent dosing compared with short‑acting octreotide formulations.

Lanreotid Amdipharm should be stored in a refrigerator at 2 °C to 8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 minutes.

The medication is supplied for subcutaneous injection. A healthcare professional prepares the dose according to the prescriber’s instructions and administers it into the subcutaneous tissue, typically in the abdomen or thigh. Patients should be trained on proper injection technique and site rotation to minimise local reactions.

Serious adverse events, although uncommon, include gallbladder disease (gallstones or sludge), hyperglycaemia or new‑onset diabetes, acute pancreatitis, severe allergic reactions such as anaphylaxis, and cardiac arrhythmias. Prompt medical evaluation is required if any of these symptoms develop during therapy.

Lanreotid Amdipharm is contraindicated in patients with known hypersensitivity to lanreotide acetate or any excipients in the formulation. Caution is also advised for individuals with severe uncontrolled diabetes, active gallbladder disease, or significant cardiac conduction abnormalities, and it should be avoided in pregnancy unless clearly justified.